Evidence map›Paper›PMID 39398357›Full record

ArticleClinical and translational radiation oncology2024

Definitive particle therapy using protons or carbon ions for dedifferentiated liposarcoma.

Hikaru Kubota, Yusuke Demizu, Kazuma Iwashita, Nobuyoshi Fukumitsu, Daiki Takahashi, SungChul Park, Shintaro Tsuruoka, Yoshiro Matsuo, Kazuki Terashima, Sunao Tokumaru and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hikaru KubotaDepartment of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, 1-6-8 Minatojima-Minamimachi, Chuo-ku, Kobe City, Hyogo, Japan.
Yusuke DemizuDepartment of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, 1-6-8 Minatojima-Minamimachi, Chuo-ku, Kobe City, Hyogo, Japan.
Kazuma IwashitaDepartment of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, 1-6-8 Minatojima-Minamimachi, Chuo-ku, Kobe City, Hyogo, Japan.
Nobuyoshi FukumitsuDepartment of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, 1-6-8 Minatojima-Minamimachi, Chuo-ku, Kobe City, Hyogo, Japan.
Daiki TakahashiDepartment of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Koto, Shingu-cho, Tatsuno City, Hyogo, Japan.
SungChul ParkDepartment of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Koto, Shingu-cho, Tatsuno City, Hyogo, Japan.
Shintaro TsuruokaDepartment of Radiology, Ehime University Hospital, 454 Shitsukawa, Toon City, Ehime, Japan.
Yoshiro MatsuoDepartment of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Koto, Shingu-cho, Tatsuno City, Hyogo, Japan.
Kazuki TerashimaDepartment of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Koto, Shingu-cho, Tatsuno City, Hyogo, Japan.
Sunao TokumaruDepartment of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Koto, Shingu-cho, Tatsuno City, Hyogo, Japan.
Tomoaki OkimotoDepartment of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Koto, Shingu-cho, Tatsuno City, Hyogo, Japan.
Toshinori SoejimaDepartment of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, 1-6-8 Minatojima-Minamimachi, Chuo-ku, Kobe City, Hyogo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Particle therapy is effective for the treatment of soft tissue sarcomas. However, the clinical outcomes of definitive particle therapy, particularly for dedifferentiated liposarcoma (DDLS), remain unknown. Purpose: To analyze the treatment outcomes of proton and carbon ion particle therapies for DDLS. Methods: We retrospectively included patients with DDLS who were treated with particle therapy between 2008 and 2022. The local control (LC), progression-free survival (PFS), and overall survival (OS) rates were evaluated. Results: Fifty-seven patients were included in this analysis. The median patient age was 68 years (range, 36-91 years). The most common tumor site was the retroperitoneum (n = 37), with a median gross tumor volume (GTV) of 181 cm Conclusions: Particle therapy using protons or carbon ions for the treatment of DDLS is safe and provides good OS and LC. However, further studies with longer follow-up periods and larger cohorts are warranted.

Indexed as

CarbonHeavy ion therapyLiposarcomaProton therapyRadiotherapySarcomaTreatment outcome

Identifiers

PMID39398357
PMCPMC11470257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.